Novo Nordisk at a glance

Novo Nordisk is a global healthcare company with more than 90 years innovation and leadership in diabetes care.



  • A focused pharmaceutical company with leading positions in diabetes, obesity, haemophilia and growth hormone
  • Significant growth opportunities driven by the diabetes pandemic, fuelled by global presence and strong R&D pipeline
  • High barriers to entry in biologics
  • Operating profit growth targeting 5% on average
  • Earnings conversion to cash targeting 85%
  • Cash generated returned to shareholders

Facts and figures


Affiliates or offices in 80 countries

Approximately 43,200 employees (February 2019)


More information

Corporate Governance

Novo Nordisk tax strategy (pdf)

Novo Nordisk Way